Information:
Fel:
ID
45392
Beskrivning
Principal Investigator: Richard Weinshilboum, MD, Mayo Clinic MeSH: Leukemia, Lymphoid https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000621 The ECOG 2997 trial was a randomized controlled trial for patients with previously untreated CLL comparing fludarabine monotherapy to the combination of fludarabine and cyclophosphamide. The initial clinical findings of this study were published in the Journal of Clinical Oncology in 2007 (JCO 25:793-8). Additional laboratory studies have also published (JCO 25:799-804).
Länk
Nyckelord
Versioner (1)
- 2022-11-15 2022-11-15 - Simon Heim
Rättsinnehavare
Richard Weinshilboum, MD, Mayo Clinic
Uppladdad den
15 november 2022
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
dbGaP phs000621 Genome Wide Association Studies in ECOG 2997 Trial
Subject ID, age, sex, best confirmed response for treatment, progression-free survival censor, progression-free survival time, survival censor variable, toxicity due to grade 4 neutropenia, total number of treatment cycles, and rice of participants with untreated chronic lymphocytic leukemia and involved in the "Genome Wide Association Studies in ECOG 2997 Trial" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, subject source, subject source ID, and affection status of participants with untreated chronic lymphocytic leukemia and involved in the "Genome Wide Association Studies in ECOG 2997 Trial" project.
- Subject ID, sample ID, plate for genotype, well within plate, sample source, sample source ID, and sample use variable of participants with untreated chronic lymphocytic leukemia and involved in the "Genome Wide Association Studies in ECOG 2997 Trial" project.
- Subject ID, age, sex, best confirmed response for treatment, progression-free survival censor, progression-free survival time, survival censor variable, toxicity due to grade 4 neutropenia, total number of treatment cycles, and rice of participants with untreated chronic lymphocytic leukemia and involved in the "Genome Wide Association Studies in ECOG 2997 Trial" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status, histological type of sample, primary metastatic tumor, primary tumor location, tumor stage, tumor grade, treatment of tumors obtained from participants with untreated chronic lymphocytic leukemia and involved in the "Genome Wide Association Studies in ECOG 2997 Trial" project.
Similar models
Subject ID, age, sex, best confirmed response for treatment, progression-free survival censor, progression-free survival time, survival censor variable, toxicity due to grade 4 neutropenia, total number of treatment cycles, and rice of participants with untreated chronic lymphocytic leukemia and involved in the "Genome Wide Association Studies in ECOG 2997 Trial" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, subject source, subject source ID, and affection status of participants with untreated chronic lymphocytic leukemia and involved in the "Genome Wide Association Studies in ECOG 2997 Trial" project.
- Subject ID, sample ID, plate for genotype, well within plate, sample source, sample source ID, and sample use variable of participants with untreated chronic lymphocytic leukemia and involved in the "Genome Wide Association Studies in ECOG 2997 Trial" project.
- Subject ID, age, sex, best confirmed response for treatment, progression-free survival censor, progression-free survival time, survival censor variable, toxicity due to grade 4 neutropenia, total number of treatment cycles, and rice of participants with untreated chronic lymphocytic leukemia and involved in the "Genome Wide Association Studies in ECOG 2997 Trial" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status, histological type of sample, primary metastatic tumor, primary tumor location, tumor stage, tumor grade, treatment of tumors obtained from participants with untreated chronic lymphocytic leukemia and involved in the "Genome Wide Association Studies in ECOG 2997 Trial" project.
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
SUBJID
Item
De-identified subject ID
text
C4684638 (UMLS CUI [1,1])
C2348585 (UMLS CUI [1,2])
C2348585 (UMLS CUI [1,2])
age
Item
Age at Entry
text
C0001779 (UMLS CUI [1,1])
sex
Item
Sex
text
C0079399 (UMLS CUI [1,1])
resp
Item
Best confirmed response
text
C2986560 (UMLS CUI [1,1])
C0750484 (UMLS CUI [1,2])
C0750484 (UMLS CUI [1,2])
pfs_cns
Item
Progression-free survival censor variable
text
C0242792 (UMLS CUI [1,1])
C3889990 (UMLS CUI [1,2])
C0439828 (UMLS CUI [1,3])
C3889990 (UMLS CUI [1,2])
C0439828 (UMLS CUI [1,3])
pfs_day
Item
Progression-free survival time variable
text
C0242792 (UMLS CUI [1,1])
C0040223 (UMLS CUI [1,2])
C0439828 (UMLS CUI [1,3])
C0040223 (UMLS CUI [1,2])
C0439828 (UMLS CUI [1,3])
os_day
Item
Overall survival time variable
text
C4086681 (UMLS CUI [1,1])
C0040223 (UMLS CUI [1,2])
C0439828 (UMLS CUI [1,3])
C0040223 (UMLS CUI [1,2])
C0439828 (UMLS CUI [1,3])
surv
Item
Overall survival censor variable
text
C4086681 (UMLS CUI [1,1])
C3889990 (UMLS CUI [1,2])
C0439828 (UMLS CUI [1,3])
C3889990 (UMLS CUI [1,2])
C0439828 (UMLS CUI [1,3])
neutrotox
Item
Toxicity due to Grade 4 Neutropenia
text
C0600688 (UMLS CUI [1,1])
C1556691 (UMLS CUI [1,2])
C1556691 (UMLS CUI [1,2])
totcyc
Item
Total Number of treatment cycles
text
C2045831 (UMLS CUI [1,1])
ncirace
Item
NCI Race
text
C1513882 (UMLS CUI [1,1])
C3853635 (UMLS CUI [1,2])
C3853635 (UMLS CUI [1,2])